Eli Lilly and Company $LLY Shares Sold by Rockland Trust Co.

Rockland Trust Co. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 2.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 15,853 shares of the company’s stock after selling 450 shares during the period. Rockland Trust Co.’s holdings in Eli Lilly and Company were worth $18,343,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of LLY. BlackRock Inc. grew its holdings in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after buying an additional 1,046,558 shares in the last quarter. State Street Corp raised its position in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after buying an additional 605,752 shares during the last quarter. Capital World Investors lifted its stake in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the period. Bank of America Corp DE purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after acquiring an additional 137,364 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded Jaypirca (pirtobrutinib) approval to first-line treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion. The decision, supported by Phase 3 BRUIN CLL-313 results, broadens Lilly’s commercial opportunity in blood cancer and strengthens its oncology portfolio. FDA Expands Eli Lilly’s Blood Cancer Drug Label in First-Line Setting
• Positive Sentiment: Lilly continues to show momentum in obesity care. Reports highlight strong patient growth and market-share gains against Novo Nordisk, while early data for next-generation treatments targeting the amylin pathway suggest potential for future combination therapies beyond Zepbound. Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
• Positive Sentiment: The company expanded its multi-year collaboration with Gate Bioscience to discover small-molecule medicines for difficult-to-drug proteins, adding longer-term pipeline potential. Lilly will also present 21 dermatology studies, including encouraging durability data for Ebglyss and research involving Taltz and Zepbound. Gate Bioscience Expands Collaboration and License Agreement with Lilly
• Neutral Sentiment: Analysts and financial coverage continue to emphasize Lilly’s strong competitive position in diabetes and obesity treatments, supported by manufacturing capacity, patents and a broad pipeline. The shares’ elevated valuation means substantial future growth may already be reflected in expectations. Eli Lilly’s Valuation Has Changed
• Negative Sentiment: Several obesity-drug developments are based on early or exploratory data, so future efficacy, safety, regulatory and commercial outcomes remain uncertain. Any setbacks could weigh more heavily on LLY because its premium valuation depends on sustained growth from this market.

Analyst Ratings Changes

Several research firms recently commented on LLY. TD Cowen reiterated a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Guggenheim raised their price target on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Bank of America increased their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,311.96.

Insider Activity

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Up 1.1%

Shares of Eli Lilly and Company stock traded up $12.80 during trading hours on Monday, hitting $1,155.65. The company’s stock had a trading volume of 827,517 shares, compared to its average volume of 2,975,996. The business has a fifty day moving average of $1,176.33 and a 200 day moving average of $1,089.48. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.09 trillion, a PE ratio of 38.77, a P/E/G ratio of 1.40 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 36.66 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.